NSEGeneral Updates22 Aug 2026 · 22 Aug 2026, 02:01 pm
General Updates
Mankind Pharma Limited · MANKIND
✦ AI Summary▲ PositiveESG
Mankind Pharma Limited has informed the Exchange about General Updates, specifically an improvement in Environmental, Social and Governance (ESG) Rating from 57 to 64, classified under the 'Strong' category, and an improvement in Core ESG Rating from 60 to 71.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Mankind Pharma Limited has informed the Exchange about General Updates
Attachments (1)
📄pdf
Download →
MANKIND1_22082026140028_ESG_Rating_Crisil.pdf
View document text
August 22, 2026
BSE Limited National Stock Exchange of India Limited
P J Towers, Exchange Plaza, C-1, Block G,
Dalal Street, Bandra Kurla Complex,
Mumbai – 400 001 Bandra (E), Mumbai – 400 051
Scrip Code: 543904 Symbol: MANKIND
Dear Sir/ Madam,
Subject: Intimation of Environmental, Social and Governance Rating
Ref.: Regulation 30 & 51 of Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 (“Listing
Regulations”)
Pursuant to Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (“Listing Regulations”), read with the SEBI Master Circular
No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, we wish to inform
you that CRISIL ESG Ratings & Analytics Limited (“CRISIL ESG Ratings”), a SEBI-
registered Category-I ESG Ratings Provider, has independently assigned an Environmental,
Social and Governance (“ESG”) Rating of 64 to the Company, falling under the “Strong”
category. This represents an improvement from the Company’s previous ESG Rating of 57,
which was classified under the “Adequate” category. Further, the Company’s Core ESG
Rating has also improved to 71 from the previous rating of 60.
Please note that the Company has not engaged CRISIL ESG Ratings for obtaining the ESG
Ratings and that it has independently prepared the report based on disclosures for FY2026 and
other publicly available information about the Company.
The above disclosure is also being made available on the Company’s website at
www.mankindpharma.com.
This is for your information and records.
Thanking You,
Yours Faithfully,
For Mankind Pharma Limited
Hitesh Kumar Jain
Company Secretary &
Compliance Officer